Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (10515)	6/19/1999 7:10:00 PM
From: ewolf	Respond to of 17367

Don't put too much faith in his targets. He has a bias to the high side. Also covers ICN Pharmaceuticals where he recently suggested lowering the target price from 100 to 75.

To: LarryS who wrote (10515)	6/21/1999 2:08:00 AM
From: aknahow	Respond to of 17367

aol.marketguide.com Compare XOMA to the S & P and other biotecks. Nice for a change. Impressive even. Wish Bluegreen would just leave the other threads alone. Would be much more interesting to see if any of those that think XOMA is junk ever wake up to what's going on. Would bet that few on other threads have read the KPMG Endotoxin paper.

To: LarryS who wrote (10515)	6/22/1999 10:32:00 AM
From: aknahow	Respond to of 17367

Larry, perhaps my message on Yahoo, was too long. Don't know why anyone would imply the BBC article is bad news. It actually is the first notice we have had that the U.K. admits it has a problem with septacemia. Up till now we have been told the rate is down to 5%. Yes, the article still holds out that in some rare cases you could see 5% if you get to the right hospital soon enough. But then the article mentions up to 40% and of course we know that a Glasgow score of 8 or higher does not mean you got anywhere quick enough. Expectations have been built up in the U.K. and this article is a first step in getting people back to reality.